Fig. 6 |. Siglec-7/9 degradation suppresses tumor growth in syngeneic mouse models.

a, B16-GMCSF tumor growth and recipient mouse survival in SigE^KO (n= 11 mice) and Sig7/9⁺ (n= 7 mice per group) mice that were intratumorally administrated with PBS, (6^bio)₄-SA-M6P₄ and Sig7/9de. b, CT-2A tumor growth and mouse survival in SigE^KO (n= 13 mice) and Sig7/9⁺ mice that were intratumorally administrated with PBS (n = 12 mice) and Sig7/9de (n= 13 mice). c, MT5 tumor growth and mouse survival in SigE^KO (n= 5 mice per group) and Sig7/9⁺ (n = 5 mice per group) mice that were intratumorally administrated with PBS and Sig7/9de from day 6 every 3 days for five doses in total, and/or intraperitoneally administration with anti-CTLA4 from day 10 every 3 days for four doses in total. Average sizes of primary tumors ± SEM are presented in cubic millimeters (mm³) (a,b,c). Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple comparisons test (a,b,c). d, Flow cytometry analysis of numbers of tumor-infiltrating immune cells in the MT5 tumor model in each treatment condition at day 18 (n= 5 mice per group, as described in the methods of c). e, Analysis of MHC-II^hi/MHC-II^low ratios among tumor-infiltrating TAMs. f,g, Indicated proportions of effector/central memory (f) and progenitor stem-like/terminally differentiated CD8⁺ T cell populations (g) among TIL CD8⁺ T cells in the MT5 tumor model in each treatment condition at day 18 (n= 5 mice per group, as described in the methods of c). Data are mean ± s.d. Two-tailed unpaired Student’s t-test (d,e,f,g).